Immune checkpoint inhibitors and cardiovascular events, real world data from Belgium

Clicks: 1
ID: 323400
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #209 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Immune checkpoints are molecules that modulate the immune response. Cancer cells use these to evade detection by the immune system. In turn, immune checkpoint inhibitors (ICIs) block these molecules to enhance cytotoxic T-cell recognition against tumour antigens. Current approved ICI’s target cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and PD- ligand 1 (PD-L1) pathways. Previous studies have shown that these checkpoints are critical negative regulators of atherosclerosis, implying that blocking them could accelerate atherosclerosis, thus potentially increasing the risk of cardiovascular events (CVEs) in cancer patients. Aim The aim of this study was to gain insights in the occurrence of CVEs in patients during/after ICI treatment. Methods Via the Intermutualistic Agency, Belgian Cancer Registry and Statbel, we obtained data on 10213 patients treated with ICI for melanoma, non-small cell lung cancer, urothelial cell carcinoma and renal cell carcinoma from 2016 (year of reimbursement in Belgium) until July 2023. Endpoints were cardiovascular medication and interventions after initiation of ICI. Results We observe a 5-year cumulative incidence rate of 8% for any CVEs, including cardiac death, controlling for death from other causes as competing risk. Specifically, the 5-year cumulative incidence rate of cardiac death and percutaneous coronary intervention was 4.4% (n = 422) and 2.9% (n = 254) respectively. Although the 5-year survival rate in our population is only 23%, this seems to be a significant incidence rate. Medication for diabetes, dyslipidemia and hypertension was started in 4% (n=386), 3% (n=332) and 7% (n=729) of patients, respectively, after ICI initiation. Conclusion CVEs are an underappreciated problem in cancer patients treated with ICI. We should therefore reconsider the often-applied conservative approach, to optimize cardiovascular outcomes in a growing population with improving cancer prognosis.CI Any cardiac intervention/death Table 1-, 2-, 5-year incidence rates
Reference Key
openalex_W7172295307 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors C Blanchaert, K W Wouters, C F Franssen
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.140
URL
https://doi.org/10.1093/eurheartjsupp/suag097.140
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.